Download RTF

Publications for John Zalcberg
Publications for John Zalcberg
2016
Chandrasegaram, M., Chen, J., Price, T.,
Zalcberg, J., Sjoquist, K., Merrett, N. (2016).
Advances in Molecular Pathology and Treatment
of Periampullary Cancers. Pancreas, 45(1),
32-39. <a
href="http://dx.doi.org/10.1097/MPA.000000000
0000385">[More Information]</a>
Ferraro, D., Goldstein, D., O'Connell, R.,
Zalcberg, J., Sjoquist, K., Tebbutt, N., Grimison,
P., McLachlan, S., Lipton, L., Vasey, P., Gebski,
V., Aiken, C., et al (2016). TACTIC: a
multicentre, open-label, single-arm phase II trial
of panitumumab, cisplatin, and gemcitabine in
biliary tract cancer. Cancer Chemotherapy and
Pharmacology, 78(2), 361-367. <a
href="http://dx.doi.org/10.1007/s00280-016-308
9-4">[More Information]</a>
2015
Chan, M., Sjoquist, K., Zalcberg, J. (2015).
Clinical utility of ramucirumab in advanced
gastric cancer. Biologics (Print): targets &
therapy, 9, 93-105. <a
href="http://dx.doi.org/10.2147/BTT.S62777">[
More Information]</a>
Lee, C., Goldstein, D., Gibbs, E., Joensuu, H.,
Zalcberg, J., Verweij, J., Casali, P., Maki, R.,
Cioffi, A., Lord, S., et al (2015). Development
and validation of prognostic nomograms for
metastatic gastrointestinal stromal tumour treated
with imatinib. European Journal of Cancer,
51(7), 852-860. <a
href="http://dx.doi.org/10.1016/j.ejca.2015.02.01
5">[More Information]</a>
Sjoquist, K., Zalcberg, J. (2015). Gastric cancer:
past progress and present challenges. Gastric
Cancer, 18(2), 205-209. <a
href="http://dx.doi.org/10.1007/s10120-014-043
7-0">[More Information]</a>
Leong, S., Smithers, B., Michael, M., Gebski, V.,
Boussioutas, A., Miller, D., Simes, R., Zalcberg,
J., Haustermans, K., Lordick, F., et al (2015).
TOPGEAR: A randomised phase III trial of
perioperative ECF chemotherapy versus
preoperative chemoradiation plus perioperative
ECF chemotherapy for resectable gastric cancer
(an international, intergroup trial of the
AGITG/TROG/EORTC/NCIC CTG). BMC
Cancer, 15(1), 1-6. <a
href="http://dx.doi.org/10.1186/s12885-015-152
9-x">[More Information]</a>
2014
Ringash, J., Au, H., Siu, L., Shapiro, J., Jonker,
D., Zalcberg, J., Moore, M., Strickland, A., Kotb,
R., Jeffery, M., Shannon, J., El-Tahche, F., et al
(2014). Quality of life in patients with K-RAS
wild-type colorectal cancer: the CO.20 phase 3
randomized trial. Cancer, 120(2), 181-189. <a
href="http://dx.doi.org/10.1002/cncr.28410">[M
ore Information]</a>
Ferraro, D., Zalcberg, J. (2014). Regorafenib in
gastrointestinal stromal tumors: clinical evidence
and place in therapy. Therapeutic Advances in
Medical Oncology, 6(5), 222-228. <a
href="http://dx.doi.org/10.1177/1758834014544
892">[More Information]</a>
Carter, H., Zannino, D., Simes, R., Schofield, D.,
Howard, K., Zalcberg, J., Price, T., Tebbutt, N.
(2014). The cost effectiveness of bevacizumab
when added to capecitabine, with or without
mitomycin-C, in first line treatment of metastatic
colorectal cancer: Results from the Australasian
phase III MAX study. European Journal of
Cancer, 50(3), 535-543. <a
href="http://dx.doi.org/10.1016/j.ejca.2013.09.02
8">[More Information]</a>
Sommeijer, D., Karapetis, C., Zalcberg, J., Tu,
D., Jonker, D., Simes, R., Tebbutt, N., Yip, D.,
Price, T., O’CALLAGHAN, C. (2014). The
relationship between rash, tumour KRAS
mutation status and clinical and quality of life
outcomes in patients with advanced colorectal
cancer treated with cetuximab in the NCIC
CTG/AGITG CO.17. Acta Oncologica, 53(7),
877-884. <a
href="http://dx.doi.org/10.3109/0284186X.2013.
879202">[More Information]</a>
2013
Vickers, M., Karapetis, C., Tu, D., O'Callaghan,
C., Price, T., Tebbutt, N., van Hazel, G., Shapiro,
J., Pavlakis, N., Gibbs, P., Simes, R., et al
(2013). Association of hypomagnesemia with
inferior survival in a phase III, randomized study
of cetuximab plus best supportive care versus
best supportive care alone: NCIC CTG/AGITG
CO.17. Annals of Oncology, 24(4), 953-960. <a
href="http://dx.doi.org/10.1093/annonc/mds577"
>[More Information]</a>
Sjoquist, K., Zalcberg, J. (2013). Clinical Trials Advancing National Cancer Care. Cancer
Forum, 37(1), 80-87.
Siu, L., Shapiro, J., Jonker, D., Karapetis, C.,
Zalcberg, J., Simes, R., Couture, F., Moore, M.,
Price, T., Siddiqui, J., et al (2013). Phase III
Randomized, Placebo-Controlled Study of
Cetuximab Plus Brivanib Alaninate Versus
Cetuximab Plus Placebo in PatientsWith
Metastatic, Chemotherapy-Refractory,
Wild-TypeK-RASColorectal Carcinoma: The
NCIC Clinical Trials Group and AGITG CO.20
Trial. Journal of Clinical Oncology, 31(19),
2477-2484. <a
href="http://dx.doi.org/10.1200/JCO.2012.46.05
Publications for John Zalcberg
43">[More Information]</a>
2012
Ngan, S., Burmeister, B., Fisher, R., Solomon,
M., Goldstein, D., Joseph, D., Ackland, S.,
Schache, D., McClure, B., McLachlan, S., et al
(2012). Randomized Trial of Short-Course
Radiotherapy Versus Long-Course
Chemoradiation Comparing Rates of Local
Recurrence in Patients With T3 Rectal Cancer:
Trans-Tasman Radiation Oncology Group Trial
01.04. Journal of Clinical Oncology, 30(31),
3827-3833. <a
href="http://dx.doi.org/10.1200/JCO.2012.42.95
97">[More Information]</a>
2011
Field, K., Zalcberg, J. (2011). Biological
Markers in Patients with Early-Stage Colon
Cancer: Consensus and Controversies. Current
Colorectal Cancer Reports, 7(3), 227-240. <a
href="http://dx.doi.org/10.1007/s11888-011-010
2-5">[More Information]</a>
Clarke, S., Yip, S., Brown, C., van Hazel, G.,
Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt,
N., Buck, M., Lowenthal, R., Boland, A.,
Gebski, V., Simes, R., et al (2011). Single-agent
irinotecan or 5-fluorouracil and leucovorin
(FOLFIRI) as second-line chemotherapy for
advanced colorectal cancer; results of a
randomised phase II study (DaVINCI) and
meta-analysis. European Journal of Cancer,
47(12), 1826-1836. <a
href="http://dx.doi.org/10.1016/j.ejca.2011.04.02
4">[More Information]</a>
Sjoquist, K., Burmeister, B., Smithers, B.,
Zalcberg, J., Simes, R., Barbour, A., Gebski, V.
(2011). Survival after neoadjuvant chemotherapy
or
chemoradiotherapy for resectable oesophageal
carcinoma: an updated meta-analysis. The Lancet
Oncology, 12(7), 681-692. <a
href="http://dx.doi.org/10.1016/S1470-2045(11)
70142-5">[More Information]</a>
2010
De Roock, W., Jonker, D., Di Nicolantonio, F.,
Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S.,
Arena, S., Frattini, M., Piessevaux, H., Simes,
R., et al (2010). Association of KRAS p.G13D
Mutation With Outcome in Patients With
Chemotherapy-Refractory Metastatic Colorectal
Cancer Treated With Cetuximab. JAMA: The
Journal of the American Medical Association,
304(16), 1812-1820. <a
href="http://dx.doi.org/10.1001/jama.2010.1535"
>[More Information]</a>
Field, K., Zalcberg, J. (2010). Chemotherapy:
Metastatic Disease. In Czito B; Willett C
(Eds.), Rectal Cancer: International Perspectives
on Multimodality Management, (pp. 189-222).
United States: Springer Science+Business
Media.
Van Glabbeke, M., Verweij, J., Blay, J.,
Debiec-Rychter, M., Demetri, G., Heinrich, M.,
Borden, E., Blanke, C., Crowley, J., Rankin, C.,
Zalcberg, J., Simes, R., et al (2010). Comparison
of Two Doses of Imatinib for the Treatment of
Unresectable or Metastatic Gastrointestinal
Stromal Tumors: A Meta-Analysis of 1,640
Patients. Journal of Clinical Oncology, 28(7),
1247-1253. <a
href="http://dx.doi.org/10.1200/JCO.2009.24.20
99">[More Information]</a>
Tebbutt, N., Parry, M., Sourjina, T., Strickland,
A., van Hazel, G., Ganju, V., Gibbs, D., Stockler,
M., Gebski, V., Zalcberg, J. (2010). Randomised,
non-comparative phase II study of weekly
docetaxel with cisplatin and 5-fluorouracil or
with capecitabine in oesophagogastric cancer:
the AGITG ATTAX trial. British Journal of
Cancer, 102(3), 475-481. <a
href="http://dx.doi.org/10.1038/sj.bjc.6605522">
[More Information]</a>
2009
Michael, M., Price, T., Ngan, S., Ganju, V.,
Strickland, A., Muller, A., Khamly, K., Milner,
A., Dilulio, J., Matera, A., Zalcberg, J., et al
(2009). A phase I trial of
Capecitabine+Gemcitabine with radical radiation
for locally advanced pancreatic cancer. British
Journal of Cancer, 100(1), 37-43. <a
href="http://dx.doi.org/10.1038/sj.bjc.6604827">
[More Information]</a>
Au, H., Karapetis, C., O'Callaghan, C., Tu, D.,
Moore, M., Zalcberg, J., Kennecke, H., Shapiro,
J., Koski, S., Pavlakis, N., et al (2009).
Health-related quality of life in patients with
advanced colorectal cancer treated with
cetuximab: overall and KRAS-specific results of
the NCIC CTG and AGITG CO.17 Trial.
Journal of Clinical Oncology, 27(11),
1822-1828. <a
href="http://dx.doi.org/10.1200/JCO.2008.19.60
48">[More Information]</a>
Mittman, N., Au, H., Tu, D., O'Callaghan, C.,
Isogai, P., Karapetis, C., Zalcberg, J., Evans, W.,
Moore, M., Siddiqui, J., Simes, R., Tebbutt, N.,
et al (2009). Prospective Cost-Effectiveness
Analysis of Cetuximab in Metastatic Colorectal
Cancer: Evaluation of National Cancer Institute
of Canada Clinical Trials Group CO.17 Trial.
Journal of the National Cancer Institute,
101(17), 1182-1192. <a
href="http://dx.doi.org/10.1093/jnci/djp232">[M
ore Information]</a>
2008
Publications for John Zalcberg
Karapetis, C., Khambata-Ford, S., Jonker, D.,
O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R.,
Chalchal, H., Shapiro, J., Robitaille, S., et al
(2008). K-ras Mutations and Benefit from
Cetuximab in Advanced Colorectal Cancer. New
England Journal of Medicine, 359(17),
1757-1765. <a
href="http://dx.doi.org/10.1056/NEJMoa080438
5">[More Information]</a>
Zalcberg, J., Rosen, L., Abdi, E., Davis, I.,
Gutheil, J., Schnell, F., Cesano, A., Gayko, U.,
Chen, M., Clarke, S. (2008). Role of Palifermin
in Fluorouracil-Based Therapy for Metastatic
Colorectal Cancer. Journal of Clinical Oncology,
26(8), 1386-1387. <a
href="http://dx.doi.org/10.1200/JCO.2007.15.44
92">[More Information]</a>
Cutsem, E., Dicato, M., Haustermans, K., Arber,
N., Bosset, J., Cunningham, D., De Gramont, A.,
Diaz-Rubio, E., Ducreux, M., Goldberg, R.,
Zalcberg, J. (2008). The diagnosis and
management of rectal cancer: expert discussion
and recommendations derived from the 9th
World Congress on Gastrointestinal Cancer,
Barcelona, 2007. Annals of Oncology,
19(Supplement 6), vi1-vi8. <a
href="http://dx.doi.org/10.1093/annonc/mdn358"
>[More Information]</a>
2007
Jonker, D., O’Callaghan, C., Karapetis, C.,
Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn,
M., Price, T., Simes, R., et al (2007). Cetuximab
for the Treatment of Colorectal Cancer. New
England Journal of Medicine, 357(20),
2040-2048. <a
href="http://dx.doi.org/10.1056/NEJMoa071834
">[More Information]</a>
Clarke, S., Goldstein, D., Mitchell, P., Michael,
M., Beale, P., Friedlander, M., Zalcberg, J.,
White, S. (2007). Modification of Leucovorin
Dose Within a Simplified FOLFOX Regimen
Improves Tolerability Without Compromising
Efficacy. Clinical Colorectal Cancer, 6(8),
578-582. <a
href="http://dx.doi.org/10.3816/CCC.2007.n.025
">[More Information]</a>
Gebski, V., Burmeister, B., Smithers, B., Foo,
K., Zalcberg, J., Simes, R. (2007). Survival
benefits from neoadjuvant chemoradiotherapy or
chemotherapy in oesophageal carcinoma: a
meta-analysis. Lancet Oncology, 8(3), 226-234.
<a
href="http://dx.doi.org/10.1016/S1470-2045(07)
70039-6">[More Information]</a>
2006
Mitchell, P., Goldstein, D., Michael, M., Beale,
P., Friedlander, M., Zalcberg, J., White, S.,
Thomson, J., Clarke, S. (2006). Addition of
gabapentin to a modified FOLFOX regimen does
not reduce oxaliplatin-induced neurotoxicity.
Clinical Colorectal Cancer, 6(2), 146-151. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16945171">[More Information]</a>
Debiec-Rychter, M., Sciot, R., Le Cesne, A.,
Schlemmer, M., Hohenberger, P., van Oosterom,
A., Blay, J., Leyvraz, S., Stul, M., Casali, P., et al
(2006). KIT mutations and dose selection for
imatinib in patients with advanced
gastrointestinal stromal tumours. European
Journal of Cancer, 42(8), 1093-1103. <a
href="http://dx.doi.org/10.1016/j.ejca.2006.01.03
0">[More Information]</a>
Rosen, L., Abdi, E., Davis, I., Gutheil, J.,
Schnell, F., Zalcberg, J., Cesano, A., Gayko, U.,
Chen, M., Clarke, S. (2006). Palifermin Reduces
the Incidence of Oral Mucositis in Patients With
Metastatic Colorectal Cancer Treated With
Fluorouracil-Based Chemotherapy. Journal of
Clinical Oncology, 24, 5194-5200. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17075109">[More Information]</a>
Michael, M., Thompson, M., Hicks, R., Mitchell,
P., Ellis, A., Milner, A., Di Iulio, J., Scott, A.,
Gurtler, V., Clarke, S., Zalcberg, J., et al (2006).
Relationship of Hepatic Functional Imaging to
Irinotecan Pharmacokinetics and Genetic
Parameters of Drug Elimination. Journal of
Clinical Oncology, 24(26), 4228-4235. <a
href="http://dx.doi.org/10.1080/1062936060056
9261">[More Information]</a>
Millward, M., House, C., Bowtell, D., Webster,
L., Olver, I., Gore, M., Copeman, M., Lynch, K.,
Yap, A., Wang, Y., et al (2006). The multikinase
inhibitor midostaurin (PKC412A) lacks activity
in metastatic melanoma: a phase IIA clinical and
biologic study. British Journal of Cancer, 95(7),
829-834. <a
href="http://dx.doi.org/10.1038/sj.bjc.6603331">
[More Information]</a>
2005
Mitchell, P., Goldstein, D., Michael, M., Beale,
P., Friedlander, M., Zalcberg, J., White, S.,
Clarke, S. (2005). Addition of gabapentin (G) to
a modified FOLFOX regimen does not reduce
neurotoxicity in patients (pts) with advanced
colorectal cancer (CRC). Journal of Clinical
Oncology, 23(No 16S (June 1 Supplement)),
3581-3581.
Goldstein, D., Mitchell, P., Michael, M., Beale,
P., Friedlander, M., Zalcberg, J., White, S.,
Clarke, S. (2005). Australian experience of a
modified schedule of FOLFOX with high
activity and tolerability and improved
Publications for John Zalcberg
convenience in untreated metastatic colorectal
cancer patients. British Journal of Cancer, 92(5),
832-837. <a
href="http://dx.doi.org/10.1038/sj.bjc.6602426">
[More Information]</a>
Zalcberg, J., Verweij, J., Casali, P., Le Cesne, A.,
Reichardt, P., Blay, J., Schlemmer, M., Van
Glabbeke, M., Brown, M., Judson, I., et al
(2005). Outcome of patients with advanced
gastro-intestinal stromal tumours crossing over
to a daily imatinib dose of 800 mg after
progression on 400 mg. European Journal of
Cancer, 41(12), 1751-1757. <a
href="http://dx.doi.org/10.1016/j.ejca.2005.04.03
4">[More Information]</a>
2002
Cunningham, D., Zalcberg, J., Maroun, J., James,
R., Clarke, S., Maughan, T., Vincent, M., Schulz,
J., Gonzalez Baron, M., Facchini, T. (2002).
Efficacy, tolerability and management of
raltitrexed (Tomudex TM) monotherapy in
patients with advanced colorectal cancer: a
review of phase II/III trials. European Journal of
Cancer, 38(4), 478-486. <a
href="http://dx.doi.org/10.1016/S0959-8049(01)
00413-0">[More Information]</a>
Rischin, D., Ackland, S., Smith, J., Garg, M.,
Clarke, S., Millward, M., Toner, G., Zalcberg, J.
(2002). Phase I and pharmacokinetic study of
docetaxel in combination with epirubicin and
cyclophosphamide in advanced cancer: dose
escalation possible with granulocyte
colony-stimulating factor, but not with
prophylactic antibodies. Annals of Oncology,
13(11), 1810-1818. <a
href="http://dx.doi.org/10.1093/annonc/mdf305"
>[More Information]</a>
2000
Rischin, D., Boyer, M., Smith, J., Millward, M.,
Michael, M., Bishop, J., Zalcberg, J., Davison, J.,
Emmett, E., McClure, B. (2000). A phase I trial
of docetaxel and gemcitabine in patients with
advanced cancer. Annals of Oncology, 11,
421-426.